Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with Sanofi for COVID-19 vaccines in exchange for a stake that doubles the U.

Novavax, Inc., a biotechnology company headquartered in Gaithersburg, Maryland, revealed on Friday, May 10, that it has signed a licensing deal with Sanofi, a global healthcare company. The deal is reportedly worth up

Sanofi on Friday announced it has reached a licensing agreement with Novavax to sell a stand-alone COVID-19 vaccine and develop new flu-COVID-19 combination vaccines while also taking an equity stake in its US peer.

The French pharmaceutical giant will work with Novavax to commercialize its existing COVI-19 vaccine and help develop a new combined vaccine for

Sanofi and Novavax Inc. signed a licensing agreement that includes commercializing a combined Covid-19 and flu shot.

Sanofi on Friday announced it has reached a 'co-exclusive' licensing agreement with Novavax to sell a stand-alone COVID-19 vaccine and develop new flu-COVID-19 combination vaccines. "We're excited by the prospect of combining Novavax's adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability,

The deal will allow Novavax to lift its "going concern" warning, which it first issued in 2023 due to having "substantial doubt" about its ability to survive.